Healthcare / BiotechnologyNYSE American
$0.64
+0.00 (+0.00%)
FCF base 3Y
n/d
n/d CAGR · yield n/d
FCF base 5Y
n/d
n/d base · n/d expected
Precio de entrada
n/d
MOS 32% · confianza 25%
FCF escenarios
weak_data · normalized FCF $-15.5M · quality 34.7/100
Ranking barato/determinista: CAGR esperado 5Y + downside bear + calidad del modelo + balance + capital allocation + data gate. No entra en buy-candidate si la data es débil o el CAGR 5Y no compensa.
SA Score
0/100
F
Piotroski
3/9
balance/quality
Valuation
50/100
+0.0% upside
5Y CAGR
+0.0%
50/100
Data QA
20/100
SEC 0%
Sin guardar todavía.
Market Cap
$4M
P/E
N/A
•EV/EBITDA
N/A
•ROE
-214.2%
↓Gross Margin
N/A
•Debt/Equity
N/A
•Absolute Values (Left Axis)
Ratios / Percentages (Right Axis)
Financial statement dashboard
2013–2025 · 12 años de histórico normalizado
Revenue CAGR
—
FCF CAGR
—
FCF margin
—
FCF / Net income
—
Latest source
Provider fallback
Margin decomposition
Último año: revenue — · net income $-10.3M · FCF —
Gross margin
Operating margin
Net margin
FCF margin
| Metric | TTM | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 | 2013 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Income Statement | ||||||||||||||
| Revenue | — | — | — | $1.1M | $3.2M | $33000.00 | $158333.00 | $89812.00 | $119750.00 | $149687.00 | $0.00 | $194494.00 | $0.00 | — |
| Net Income | $-10.3M | $-10.3M | $-24.3M | $-22.9M | $-21.0M | $-23.3M | $-22.4M | $-17.4M | $-14.1M | $-15.5M | $-7.6M | $-9.1M | $-10.2M | $-3.7M |
| EBITDA | $-6.9M | $-6.9M | $-24.2M | $-23.4M | $-24.3M | $-24.5M | $-24.0M | $-18.7M | $-14.4M | $-16.4M | $-8.2M | $-9.9M | $-10.4M | — |
| EPS | -2.00 | -2.00 | -4.98 | -5.28 | -0.10 | -0.11 | — | — | — | — | — | — | — | — |
| Operating Margin | — | — | — | -2168.4% | -771.3% | -74954.5% | -15288.4% | -21067.4% | -12230.9% | -11024.6% | — | -5096.0% | — | — |
| Net Margin | — | — | — | -2093.2% | -658.6% | -70554.5% | -14177.0% | -19343.4% | -11760.4% | -10345.9% | — | -4697.0% | — | — |
| Cash Flow | ||||||||||||||
| Free Cash Flow | — | — | — | $-15.5M | $-20.0M | $-15.5M | $-17.4M | $-14.5M | $-10.9M | $-12.4M | $-6.1M | $-7.9M | — | — |
| Returns | ||||||||||||||
| ROE | -214.2% | -214.2% | -319.5% | -119.2% | -57.3% | -44.4% | -35.2% | -52.6% | -87.2% | -145.0% | -106.3% | -150.4% | -458.8% | -35.4% |
| Growth & Yield | ||||||||||||||
| Revenue Growth | — | — | — | -65.6% | 9560.6% | -79.2% | 76.3% | -25.0% | -20.0% | — | -100.0% | — | — | — |
| EPS Growth | 59.8% | 59.8% | 5.7% | -5180.0% | 9.1% | — | — | — | — | — | — | — | — | — |
Revenue, Net Income & Free Cash Flow ($B)
Margins (%)
Returns (%)
Qué te dice: cuánto EPS CAGR está descontando el precio si sales al múltiplo terminal indicado. Si el growth observado queda por debajo, el mercado está pidiendo una ejecución muy fina.
Unavailable: positive start/end prices are required.